RichardBertramWilberMD

Pediatric Infectious Disease • Cheshire, CT

Physician

Join to view full profile

Are you Dr. Wilber?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 26 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
100 Nob Hill Rd
Cheshire, CT 06410
Phone+1 203-271-3250
Is this information wrong?

Summary

Dr. Richard Wilber, MD is a pediatric infectious disease specialist in Cheshire, Connecticut. He is currently licensed to practice medicine in Connecticut.

Education & Training

University of TennesseeFellowship, Pediatric Infectious Diseases, 1977 - 1978
St Louis University School of MedicineResidency, Pediatrics, 1973 - 1977
Saint Louis University School of MedicineClass of 1973

Certifications & Licensure

CT State Medical License 1987 - 2016
American Board of Pediatrics Pediatrics

Publications & Presentations

PubMed

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naÃ¯ve patients is rare through 5 years of therapy.
Tenney, D.J., Rose, R.E., Baldick, C.J., Pokornowski, K.A., Eggers, B.J., Fang, J., Wichroski, M.J., Xu, D., Yang, J., Wilber, R.B., Colonno, R.J.> ;Hepatology. 2009 May
Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment.
Shyu, W. C., Pittman, K. A., Wilber, R. B., Matzke, G. R., Barbhaiya, R. H.> ;J Clin Pharmacol. 1991 Apr
Penetration of cefprozil into tonsillar and adenoidal tissues.
Shyu, W. C., Reilly, J., Campbell, D. A., Wilber, R. B., Barbhaiya, R. H.> ;Antimicrob Agents Chemother. 1993 May
Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans.
Shyu, W. C., Shah, V. R., Campbell, D. A., Wilber, R. B., Pittman, K. A., Barbhaiya, R. H.> ;J Clin Pharmacol. 1992 Sep
Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.
Barbhaiya, R. H., Shukla, U. A., Gleason, C. R., Shyu, W. C., Wilber, R. B., Pittman, K. A.> ;Antimicrob Agents Chemother. 1990 Jun
Phase I study of multiple-dose cefprozil and comparison with cefaclor.
Barbhaiya, R. H., Shukla, U. A., Gleason, C. R., Shyu, W. C., Wilber, R. B., Martin, R. R., Pittman, K. A.> ;Antimicrob Agents Chemother. 1990 Jun
Pharmacokinetics of cefprozil in healthy subjects and patients with hepatic impairment.
Shyu, W. C., Wilber, R. B., Pittman, K. A., Garg, D. C., Barbhaiya, R. H.> ;J Clin Pharmacol. 1991 Apr
Effect of antacid on the bioavailability of cefprozil.
Shyu, W. C., Wilber, R. B., Pittman, K. A., Barbhaiya, R. H.> ;Antimicrob Agents Chemother. 1992 May
Excretion of cefprozil into human breast milk.
Shyu, W. C., Shah, V. R., Campbell, D. A., Venitz, J., Jaganathan, V., Pittman, K. A., Wilber, R. B., Barbhaiya, R. H.> ;Antimicrob Agents Chemother. 1992 May
Safety profile of cefprozil.
Wilber, R. B., Doyle, C. A., Durham, S. J., Conetta, B. J., DeGraw, S. S., Leigh, A.> ;Clin Infect Dis. 1992 Jun
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung, N., Peng, C. Y., Hann, H. W., Sollano, J., Lao-Tan, J., Hsu, C. W., Lesmana, L., Yuen, M. F., Jeffers, L., Sherman, M., Min, A., Mencarini, K., Diva, U., Cross,...> ;Hepatology. 2009 Jan 01
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang, T. T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y. C., Lok, A. S., Han, K. H., Goodman, Z., Zhu, J., Cross, A., DeHertogh, D., Wilber, R., Colonn...> ;N Engl J Med. 2006 Mar 9
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Lai, C. L., Shouval, D., Lok, A. S., Chang, T. T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., Colonno, R., Fernandes, L.> ;N Engl J Med. 2006 Mar 9
Join now to see all